Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestogen presented as a 52 mg intrauterine system (IUS) for intrauterine use. Approved in the European Union, it delivers a steady low dose of hormone to provide long‑acting reversible contraception for women of reproductive age, reducing the need for daily pills.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide under strict quality‑assured conditions. All shipments follow WHO‑GMP guidelines and are supported by a dedicated regulatory affairs team.

Levosert, containing levonorgestrel, is used as a hormonal contraceptive to prevent pregnancy. - Contraception: Provides up to five years of highly effective reversible birth control. - Post‑abortion contraception: Offers immediate, reliable contraception following surgical or medical abortion. - Family planning: Enables long‑term pregnancy prevention without daily pill adherence.

Levosert may be associated with a range of adverse reactions, most of which are mild and resolve without intervention.

Common Side Effects: - Irregular bleeding: Unpredictable spotting or changes in menstrual pattern. - Amenorrhea: Absence of menstrual bleeding. - Pelvic pain: Discomfort in the lower abdomen. - Headache: Mild to moderate tension‑type headaches. - Breast tenderness: Sensitivity or swelling of the breasts. - Mood changes: Slight fluctuations in mood or irritability.

Serious or Rare Side Effects: - Uterine perforation: Rare injury to the uterine wall during insertion. - Ectopic pregnancy: Occurs if contraception fails and implantation is outside the uterus. - Infection: Pelvic inflammatory disease following insertion. - Allergic reaction: Severe hypersensitivity requiring medical attention. - Device expulsion: Partial or complete loss of the IUS from the uterine cavity.

Before using Levosert, clinicians should evaluate patient history and follow recommended safety measures. - Pregnancy status: Confirm the patient is not pregnant before insertion. - Uterine abnormalities: Assess for fibroids, septum, or scarring that may impede placement. - Infection risk: Treat active pelvic infections prior to insertion. - Breastfeeding: Consider alternative contraception during early lactation if advised. - Smoking: Advise cessation in women over 35 who smoke, due to increased cardiovascular risk. - Storage: Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Levosert can interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): May reduce levonorgestrel efficacy. - Rifampin and other strong antibiotics: Potentially decrease hormone levels.

Moderate Interactions (Monitor Closely): - Hormonal therapies (e.g., estrogen‑containing contraceptives): May increase overall hormone exposure. - Antifungal azoles (e.g., ketoconazole): Can increase levonorgestrel concentrations. - Herbal supplements (e.g., St. John’s wort): May modestly lower effectiveness.